Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARCINOHIPEC: HIPEC with Cisplatin in Ovarian Cancer
NCT02328716Phase 3Unknown
- Sponsor
- Fundación para la Formación e Investigación Sanitaria
- Start
- Feb 2012
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cisplatin in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal carcinoma (PPC) (2 arms), sponsored by Fundación para la Formación e Investigación Sanitaria. Primary endpoint: Disease-Free Survival at 30 months. Status: unknown.
02
Drugs
cisplatin
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT02328716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02328716.